Bilateral Lung transplantation (LUTX) is performed in selected patients with end-stage respiratory failure. During surgery, pulmonary arteries are sequentially cross-clamped. This can cause acute heart failure and hemodynamic instability that eventually persist into the postoperative period, leading to the need for prolonged vasoactive support in the postoperative Intensive Care Unit. Levosimendan is a relatively new vasoactive-inotropic drug, with different pharmacodynamic properties. This observational retrospective cohort study primarily aims 1) to describe the need for prolonged vasoactive support; 2) to evaluate the risk factors for prolonged vasoactive support; 3) to assess the impact of prolonged vasoactive support on outcomes. The secondary aim is to describe the use of Levosimendan in this cohort of patients.
Study Type
OBSERVATIONAL
Enrollment
150
Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico
Milan, Italy
Need of postoperative vasoactive support after LUTX
This outcome aims to describe the number of patients treated with vasoactive drugs after Lung Transplantation in Intensive Care Unit, and median dosage and duration of therapy.
Time frame: February 2017 - July 2022
Postoperative vasoactive support use after LUTX risk factors.
This outcome aims to assess if preoperative characteristics or intraoperative events can represent risk or protecting factors for postoperative vasoactive drugs need.
Time frame: February 2017 - July 2022
Vasoactive support after LUTX impacts on outcomes.
This outcome aims to assess if the vasoactive drug use in the postoperative management of Lung Transplanted patients impacts 1) mechanical ventilation duration; 2) Continuous Renal Replacement Therapy; 3) ICU and Hospital Length of Stay; 4) Primary Graft Dysfunction; 5) in-hospital mortality; 6) survival at July 31st, 2023.
Time frame: February 2017 - July 2022
Description of Levosimendan use in post-operative LUTX patients.
This outcome aims to describe the number and the characteristics of patients treated with levosimendan.
Time frame: February 2017 - July 2022
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.